title: Thiazolidinedione use is associated with improved all-cause mortality compared with sulfonylureas among diabetic hemodialysis patients.
authors: Division of Nephrology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA; Division of Nephrology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
authors: Katherine E
authors: KE
authors: Lynch
authors: Connie M
authors: CM
authors: Rhee
authors: Steven M
authors: SM
authors: Brunelli
mesh_terms: D000368:Aged; D001786:Blood Glucose / Q000032:analysis; D003920:Diabetes Mellitus / Q000188:drug therapy* / Q000401:mortality*; D005260:Female; D005500:Follow-Up Studies; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D006435:Renal Dialysis / Q000401:mortality*; D012189:Retrospective Studies; D013453:Sulfonylurea Compounds / Q000627:therapeutic use*; D015996:Survival Rate; D045162:Thiazolidinediones / Q000627:therapeutic use*
chemical_list: D001786:Blood Glucose; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D013453:Sulfonylurea Compounds; D045162:Thiazolidinediones; C089946:2,4-thiazolidinedione
keywords: end-stage renal disease; epidemiology; pharmacotherapy; type 2 diabetes